TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7497073

Group type: EXPERIMENTAL
Intervention: Probabilistic reasoning in self‐threatening anxiety states
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Simple yes‐or‐no decisions in physically threatening anxiety states
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Self‐threatening anxiety states with probabilistic judgments
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Physically threatening anxiety states with simple yes‐or‐no judgments
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Processing styles alone
Number of subjects: 66
Study: 2153491

Group type: EXPERIMENTAL
Intervention: Adenosine infusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intact hypoxic ventilatory drive
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Attenuated chemoreflexes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 5
Study: 7224346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 38
Study: 31800752

Group type: EXPERIMENTAL
Intervention: Surgical Therapy (ST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonsurgical Therapy (NST)
Number of subjects: 16
Study: 28822166

Group type: EXPERIMENTAL
Intervention: Modified Da Chaihu decoction
Number of subjects: 126

Group type: COMPARATOR
Intervention: Amlodipine besylate tablets
Number of subjects: 126

Group type: COMPARATOR
Intervention: Flupentixol and melitracen tablets
Number of subjects: 126
Study: 26432182

Group type: EXPERIMENTAL
Intervention: 225 mg TEV-48125
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: 675 mg TEV-48125
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 23582671

Group type: EXPERIMENTAL
Intervention: Early assisted discharge (discharge at day 4 with home care nurse visits until day 7)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual hospital care (discharged at day 7)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Early assisted discharge
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 139
Study: 21672926

Group type: EXPERIMENTAL
Intervention: Recombinant LH (rLH) added to controlled ovarian hyperstimulation (COH)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: One extra daily injection of rLH
Number of subjects: 206
Study: 19320829

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) 130/0.4
Number of subjects: 20
Study: 17623467

Group type: EXPERIMENTAL
Intervention: BMS-378806 (100 to 1600 mg single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-378806 (100 to 1200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-378806 (1600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-378806 with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-378806 as a solution formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-378806
Number of subjects: 0
Study: 15530201

Group type: EXPERIMENTAL
Intervention: Typing skills intervention group
Number of subjects: 311

Group type: COMPARATOR
Intervention: Daily typed journal group
Number of subjects: 311
Study: 11170143

Group type: EXPERIMENTAL
Intervention: Pathological stage
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Tumor volume
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Margin status
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Proportion of poorly differentiated cancer
Number of subjects: 218
Study: 9823790

Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracoronary stents
Number of subjects: 0
Study: 7827218

Group type: EXPERIMENTAL
Intervention: Panic disorder patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 50
Study: 3415803

Group type: EXPERIMENTAL
Intervention: Tertatolol (5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nadolol (80 mg)
Number of subjects: 8
Study: 31421024

Group type: EXPERIMENTAL
Intervention: Treat-and-extend protocol with moderate extensions (T&Em)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Treat-and-extend protocol with rapid extensions (T&Er)
Number of subjects: 52
Study: 29252047

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR; 140 ml/day, ∼800 mg/day nitrate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 14
Study: 26573267

Group type: EXPERIMENTAL
Intervention: Use of CPRmeter® device
Number of subjects: 88

Group type: COMPARATOR
Intervention: No use of CPRmeter® device (Control Group A)
Number of subjects: 88
Study: 24636143

Group type: EXPERIMENTAL
Intervention: Group manual‐course (GMC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group manual‐orientations (GMO)
Number of subjects: 40
Study: 23413606

Group type: EXPERIMENTAL
Intervention: Novel pharmacological options targeting androgen signaling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel radioisotope therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytotoxic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions targeting new molecular pathways
Number of subjects: 0
Study: 21353117

Group type: EXPERIMENTAL
Intervention: New generic formulation of bicalutamide 50-mg tablets (test)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Currently marketed formulation of bicalutamide 50-mg tablets (reference)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 32
Study: 18083505

Group type: EXPERIMENTAL
Intervention: Lycopus europaeus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17309908

Group type: EXPERIMENTAL
Intervention: Gentamicin 2 mg/kg, rifampicin 600 mg, vancomycin 15 mg/kg (with three further doses of 7.5 mg/kg at 12-hour intervals)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g at induction and three further doses of 750 mg at 8-hour intervals
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Gentamicin, rifampicin, vancomycin
Number of subjects: 186
Study: 12925049

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ANP (0.25 microg/kg/min in 0.9% NaCl) after 3 weeks' pre‐treatment with placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous infusion of vehicle (0.9% NaCl only) after 3 weeks' pre‐treatment with placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ANP (0.25 microg/kg/min in 0.9% NaCl) after 3 weeks' pre‐treatment with perindopril, 4 mg daily
Number of subjects: 7
Study: 10840536

Group type: EXPERIMENTAL
Intervention: Tropisetron 0.1 mg/kg body weight
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 9088077

Group type: EXPERIMENTAL
Intervention: LeukoNet prestorage leukoreduction filtration system
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (non-leukoreduced units)
Number of subjects: 21
Study: 8448775

Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 10

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sucrose gum
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sorbitol gum
Number of subjects: 10
Study: 3082591

Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (5 subjects)
Number of subjects: 5
Study: 29555789

Group type: EXPERIMENTAL
Intervention: Haemodynamic management targeting StO2 >80%
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no targeting StO2)
Number of subjects: 103
Study: 28394110

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: No corticosteroid therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 40
Study: 24489014

Group type: EXPERIMENTAL
Intervention: 30 mg ORM-12741
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg ORM-12741
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22828645

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT booster dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenC-TT booster dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: MenC-CRM197 (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT and MenC-TT
Number of subjects: 0
Study: 20153487

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 10
Study: 18991470

Group type: EXPERIMENTAL
Intervention: TT (timolol/travoprost)
Number of subjects: 316

Group type: COMPARATOR
Intervention: TL (timolol/latanoprost)
Number of subjects: 316
Study: 15489260

Group type: EXPERIMENTAL
Intervention: Endurance-trained (ET) men
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary (Sed) men
Number of subjects: 36
Study: 14673126

Group type: EXPERIMENTAL
Intervention: AUDIT
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: CDT
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: GGT
Number of subjects: 990
Study: 9888118

Group type: EXPERIMENTAL
Intervention: Daily contingent condition (earn a 1-day take-home privilege for each opiate and cocaine-free test delivered)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Weekly contingent condition (three negative test results required for the first take-home privilege)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No take-home control
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Daily contingent condition
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Weekly contingent condition
Number of subjects: 21
Study: 8665128

Group type: EXPERIMENTAL
Intervention: Zamifenacin 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized planimetry
Number of subjects: 0
Study: 1642946

Group type: EXPERIMENTAL
Intervention: Reflective blankets
Number of subjects: 30

Group type: COMPARATOR
Intervention: No reflective blankets (Control)
Number of subjects: 30
Study: 6099050

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 200 mg/day combined with gestagen at 50 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: High dose estrogen (hexestrol at 60 mg/day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 200 mg/day combined with hexestrol at 30 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: High dose estrogen (hexestrol at 60 mg/day) in patients already well controlled
Number of subjects: 56
Study: 31147254

Group type: EXPERIMENTAL
Intervention: Orthostatic Hypotension (OH)
Number of subjects: 2275
Study: 28646804

Group type: EXPERIMENTAL
Intervention: Stress-reduction program (EBT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intuitive eating (IE)
Number of subjects: 33
Study: 27339107

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution (CHO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 16% carbohydrate solution (CHO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0% control (PLA)
Number of subjects: 12
Study: 24680406

Group type: EXPERIMENTAL
Intervention: BiPAP
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: SBiPAP
Number of subjects: 107

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 107
Study: 22929967

Group type: EXPERIMENTAL
Intervention: Microneedle treatment + daily topical application of diclofenac sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20207879

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (N = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Yogurt fluid (YF) (N = 27)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 55

Group type: COMPARATOR
Intervention: Yogurt fluid (YF)
Number of subjects: 55
Study: 17510867

Group type: EXPERIMENTAL
Intervention: CO(2) laser transconjunctival blepharoplasty with resurfacing
Number of subjects: 36

Group type: COMPARATOR
Intervention: CO(2) laser transcutaneous blepharoplasty by the skin‐muscle approach without resurfacing
Number of subjects: 36
Study: 15913543

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 59
Study: 11814510

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Surgical therapy for prolapse
Number of subjects: 343

Group type: COMPARATOR
Intervention: Overall sexual satisfaction
Number of subjects: 343
Study: 9585947

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 7650101

Group type: EXPERIMENTAL
Intervention: Neglect rehabilitation training for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: General cognitive stimulation for 2 months (Control)
Number of subjects: 0
Study: 2777423

Group type: EXPERIMENTAL
Intervention: Ibopamine 0.25%
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ibopamine 0.50%
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ibopamine 1%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tropicamide 1%
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1103551

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin
Number of subjects: 0
Study: 31925942

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Number of subjects: 3412

Group type: EXPERIMENTAL
Intervention: Nomograms for PFS and OS
Number of subjects: 3412
Study: 31070463

Group type: EXPERIMENTAL
Intervention: Ropivacaine with clonidine 2 μg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine and a subcutaneous injection of clonidine 2 μg/kg (SC clonidine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine with 1:400,000 adrenaline
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.2% ropivacaine (control)
Number of subjects: 80
Study: 28403589

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide 300 mg plus Alpha‐lipoic acid 300 mg (Peanase®)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Serenoa Repens at 320 mg
Number of subjects: 44
Study: 25456116

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 μg · kg(‐1) initial dose followed by 0.4 μg · kg(‐1) h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline infusion (NS group)
Number of subjects: 40
Study: 23832382

Group type: EXPERIMENTAL
Intervention: Basal right ventricular (RV) entrainment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Apical right ventricular (RV) entrainment
Number of subjects: 42
Study: 21743879

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 46
Study: 19186907

Group type: EXPERIMENTAL
Intervention: Fit information customization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Configural customization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Either or both forms of customization
Number of subjects: 0
Study: 16702079

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1
Study: 10225157

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 90
Study: 8934993

Group type: EXPERIMENTAL
Intervention: Combination IAN block and PDL injections using 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combination IAN block and mock PDL injections (needle penetration only)
Number of subjects: 40
Study: 1927301

Group type: EXPERIMENTAL
Intervention: Laser evaporation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Cryocoagulation
Number of subjects: 204
Study: 6957127

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30638863

Group type: EXPERIMENTAL
Intervention: VIS410 4000 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: VIS410 2000 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 30073693

Group type: EXPERIMENTAL
Intervention: Low dose cyclosporine A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose cyclosporine A
Number of subjects: 0
Study: 27806350

Group type: EXPERIMENTAL
Intervention: Enteral Docosahexaenoic Acid (DHA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sunflower Oil (SO)
Number of subjects: 35
Study: 25304255

Group type: COMPARATOR
Intervention: Educational material (usual care comparison)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Feedback of practice rates of high-risk prescribing
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Theory-informed behaviour change component
Number of subjects: 262
Study: 22152405

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21198224

Group type: EXPERIMENTAL
Intervention: BASICS
Number of subjects: 207

Group type: COMPARATOR
Intervention: Alcohol 101
Number of subjects: 207

Group type: COMPARATOR
Intervention: e-CHUG
Number of subjects: 207

Group type: COMPARATOR
Intervention: Assessment-only
Number of subjects: 207
Study: 17674638

Group type: EXPERIMENTAL
Intervention: Dr. Dean Ornish Program for Reversing Heart Disease
Number of subjects: 93

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation
Number of subjects: 93
Study: 16140544

Group type: EXPERIMENTAL
Intervention: sublingual piroxicam‐FDDF 20 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: oral azithromycin 500 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: piroxicam‐FDDF 20 mg/day plus azithromycin 500 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: piroxicam‐FDDF 20 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: azithromycin 500 mg/day
Number of subjects: 30
Study: 12047415

Group type: EXPERIMENTAL
Intervention: BMS‐284756 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BMS‐284756 200 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BMS‐284756 400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BMS‐284756 800 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BMS‐284756 1200 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BMS‐284756 (all doses)
Number of subjects: 40
Study: 10209367

Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Gas mix (nitrous oxide and oxygen)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 3
Study: 7603807

Group type: EXPERIMENTAL
Intervention: Oral glycerol (GLY)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Intravenous dexamethasone (DXM)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Neither treatment (Control)
Number of subjects: 122
Study: 2168694

Group type: EXPERIMENTAL
Intervention: Hepatic resection after serologic remission
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Concomitant cytoreductive procedures
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Histologic classification system
Number of subjects: 28
Study: 30562274

Group type: EXPERIMENTAL
Intervention: Toric contact lenses (1‐Day ACUVUE MOIST for astigmatism)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spherical contact lenses (1‐Day ACUVUE MOIST)
Number of subjects: 60
Study: 28500020

Group type: EXPERIMENTAL
Intervention: Web-based self-guided app recommendation service ('The Toolbox')
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 387
Study: 27100702

Group type: EXPERIMENTAL
Intervention: Aided suppression (substitute words provided)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Unaided suppression (no substitute words provided)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dysphoric participants
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-dysphoric participants
Number of subjects: 72
Study: 23775755

Group type: EXPERIMENTAL
Intervention: High-impact exercise (supervised progressive exercise three times a week for 12 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-impact exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 21909816

Group type: EXPERIMENTAL
Intervention: Adrenaline-saline solution 1:200,000
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 61
Study: 20555371

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) 0.5 g.kg‐1 body mass
Number of subjects: 13
Study: 17576847

Group type: EXPERIMENTAL
Intervention: 500 mg flucloxacillin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1,000 mg flucloxacillin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 g/day continuous or prolonged infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Short-term infusions of 6 g/day
Number of subjects: 10
Study: 16361169

Group type: EXPERIMENTAL
Intervention: Thoracic small incision (average length of incision, 12.7 cm)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Standard thoracic incision (control group)
Number of subjects: 386
Study: 11953813

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian trial design
Number of subjects: 0
Study: 10204902

Group type: EXPERIMENTAL
Intervention: 2 mL of 2% mepivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 mL of 2% mepivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 6 mL of 2% mepivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 8 mL of 2% mepivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10 mL of 2% mepivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 12 mL of 2% mepivacaine
Number of subjects: 120